
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator in... InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0018 | 0.225846925972 | 0.797 | 0.8318 | 0.75 | 439630 | 0.78418964 | CS |
4 | -0.9812 | -55.1235955056 | 1.78 | 1.9 | 0.7113 | 964746 | 0.8028808 | CS |
12 | -0.4312 | -35.0569105691 | 1.23 | 1.92 | 0.7113 | 491106 | 1.0092894 | CS |
26 | -1.2812 | -61.5961538462 | 2.08 | 2.77 | 0.7113 | 418795 | 1.38388872 | CS |
52 | -0.6312 | -44.1398601399 | 1.43 | 2.815 | 0.7113 | 285767 | 1.54961503 | CS |
156 | -0.4212 | -34.5245901639 | 1.22 | 7.2499 | 0.7113 | 449408 | 3.4862854 | CS |
260 | -4.4512 | -84.7847619048 | 5.25 | 7.2499 | 0.7113 | 535857 | 3.75751316 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions